Last reviewed · How we verify
UX111
At a glance
| Generic name | UX111 |
|---|---|
| Also known as | scAAV9.U1a.hSGSH, ABO-102, rebisufligene etisparvovec |
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
- Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA (PHASE3)
- Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UX111 CI brief — competitive landscape report
- UX111 updates RSS · CI watch RSS
- Ultragenyx Pharmaceutical Inc portfolio CI